CO5690559A2 - BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE - Google Patents
BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATEInfo
- Publication number
- CO5690559A2 CO5690559A2 CO05013218A CO05013218A CO5690559A2 CO 5690559 A2 CO5690559 A2 CO 5690559A2 CO 05013218 A CO05013218 A CO 05013218A CO 05013218 A CO05013218 A CO 05013218A CO 5690559 A2 CO5690559 A2 CO 5690559A2
- Authority
- CO
- Colombia
- Prior art keywords
- trihydrate
- chlorhydrate
- drugs containing
- bayer healthcare
- vardenafil hydrochloride
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 3
- HKBMAKDDGMWFLB-UHFFFAOYSA-N O.O.O.OCl Chemical compound O.O.O.OCl HKBMAKDDGMWFLB-UHFFFAOYSA-N 0.000 title 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229960002381 vardenafil Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 abstract 3
- 239000012467 final product Substances 0.000 abstract 2
- 150000004684 trihydrates Chemical group 0.000 abstract 2
- 229960001540 vardenafil hydrochloride Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229960004573 vardenafil hydrochloride trihydrate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
1.- Procedimiento para la fabricación de medicamentos que contienen clorhidrato de vardenafilo trihidrato en forma sólida, caracterizado porquea) en la preparación del medicamento se utiliza clorhidrato de vardenafilo con un contenido de agua discrecional,b) el clorhidrato de vardenafilo se transforma substancialmente en la forma trihidrato en un intermedio de procesamiento o en el producto final.2.- Procedimiento conforme a la reivindicación 1, caracterizado porque como medicamento se fabrican comprimidos recubiertos.3.- Procedimiento conforme a las reivindicaciones 1 y 2, caracterizado porque el intermedio de procesamiento o el producto final o el comprimido recubierto se pone en contacto con gas humedecido el tiempo necesario para que se forme substancialmente el trihidrato.4.- Procedimiento conforme a la reivindicación 3, caracterizado porque como gas se utiliza aire.1.- Procedure for the manufacture of medicines containing vardenafil hydrochloride trihydrate in solid form, characterized in that a) in the preparation of the drug, vardenafil hydrochloride with a discretionary water content is used, b) vardenafil hydrochloride is substantially transformed into the Trihydrate form in a processing intermediate or in the final product. 2.- Method according to claim 1, characterized in that as a medicament coated tablets are manufactured. 3.- Procedure according to claims 1 and 2, characterized in that the processing intermediate or the final product or the coated tablet is contacted with moistened gas for the time necessary for the trihydrate to form substantially. 4. Method according to claim 3, characterized in that air is used as gas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5690559A2 true CO5690559A2 (en) | 2006-10-31 |
Family
ID=42138709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Country Status (1)
| Country | Link |
|---|---|
| CO (1) | CO5690559A2 (en) |
-
2005
- 2005-02-14 CO CO05013218A patent/CO5690559A2/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005631A (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases. | |
| PL1957110T3 (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
| NZ586588A (en) | Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| TNSN08279A1 (en) | Bayer healthcare ag | |
| TW200806289A (en) | Sustained-release formulation of zonisamide | |
| WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
| PE20120956A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE | |
| BRPI0513598A (en) | enteric release coated tablet dosage forms | |
| BRPI0700133A (en) | pharmaceutical composition comprising tramadol and ketoprofen in combination | |
| EA201270269A1 (en) | PHARMACEUTICAL TABLET CONTAINING ROSUVASTATIN CALCIUM | |
| BRPI0520797B8 (en) | bilayer compressed pharmaceutical dosage form | |
| CO5690559A2 (en) | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE | |
| BRPI0610780A2 (en) | disintegrating tablet pharmaceutical formulation, and methods for treating a patient in need of olanzapine treatment, and for producing the tablet pharmaceutical formulation | |
| BRPI0407850A (en) | process for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, and fenofibrate tablet or one of its derivatives | |
| CO6410284A2 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES | |
| CN201304092Y (en) | Drug-packaging box | |
| MX2010006317A (en) | Oral pharmaceutical composition with an antihistamine and decongestant. | |
| TW200638941A (en) | Processing method of nano preparation of Chinese herbal antibiotic drug | |
| PL1877035T3 (en) | Pharmaceutical composition and dosage form fast-disintegrating in the mouth , and process to prepare it | |
| EE200600045A (en) | A medicament for the treatment and prophylaxis of cancer, a pharmaceutical composition, a process for the preparation of a pharmaceutical composition | |
| ATE551998T1 (en) | SOLID PHARMACEUTICAL COMPOSITION CONTAINING TAMSULOSINE | |
| ECSP11011279A (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES | |
| JO2568B1 (en) | Novel Pharmaceutical Chitosan for use in Solid Dosage Forms | |
| UA36724U (en) | Drug formulation of dry mixture against cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |